Prilenia Therapeutics

Executive Summary

Prilenia Therapeutics is a private Israeli biopharmaceutical company developing oral sigma-1 receptor (S1R) agonists to address neurodegenerative diseases with high unmet need. Its lead asset, pridopidine, is currently in Phase 3 clinical trials for Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). The compound has a novel mechanism of action that promotes neuroprotection and functional restoration, differentiating it from existing therapies. Prilenia's pipeline also includes earlier-stage programs for rare CNS disorders. Despite the high-risk nature of CNS drug development, positive Phase 3 data could establish pridopidine as a first-in-class treatment for HD and ALS, representing a significant market opportunity. The company is privately held and has not disclosed its valuation or funding history. Key upcoming milestones include regulatory interactions and data readouts that will determine the asset's path to approval.

Upcoming Catalysts (preview)

• H1 2028Phase 3 HD Trial Top-line Results50% success
• H2 2027Phase 3 ALS Trial Interim Analysis40% success
• 2027Potential Strategic Partnership or Financing Round60% success